MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

Limited coverage is provided for high-sensitivity non-NGS single- or multi-gene tests to diagnose BCR-ABL-negative myeloproliferative neoplasms when performed according to consensus diagnostic criteria and after BCR-ABL assessment (except suspected PV). Tests must meet analytical and clinical validation requirements (including specified VAF sensitivity for JAK2, CALR, MPL), include minimum necessary genes for the suspected MPN subtype, and NGS testing is handled under a separate LCD (L38047) with allowance for NGS only when non-NGS testing is negative and additional non-duplicative alterations are required.

"Testing is covered when the patient is being evaluated for a BCR-ABL-negative myeloproliferative neoplasm according to national or international consensus diagnostic criteria (e."

Sign up to see full coverage criteria, indications, and limitations.